Malaria treatment: Halofantrine

There is still no cure for malaria, which is transmitted by infected mosquitoes. Halofantrine was developed by SRI in 1975.

SRI developed halofantrine for the U.S. Army from 1965 to 1975 as a treatment for drug-resistant malaria. Distributed by the World Health Organization (WHO), the drug has saved countless lives. The Food and Drug Administration (FDA) approved halofantrine as an antimalarial in 1992 under the SmithKline Beecham (now GlaxoSmithKline) brand name, Halfan®.

Read more from SRI

  • A rendering of the Parker Solar Probe inside the sun's corona.

    Parker Solar Probe: Our closest look at the sun

    SRI imaging technology supports a record-shattering NASA mission.

  • A photo of Mary Wagner

    Recognizing the life and work of Mary Wagner 

    A cherished SRI colleague and globally respected leader in education research, Mary Wagner leaves behind an extraordinary legacy of groundbreaking work supporting children and youth with disabilities and their families.

  • Testing XRGo in a robotics laboratory

    Robots in the cleanroom

    A global health leader is exploring how SRI’s robotic telemanipulation technology can enhance pharmaceutical manufacturing.